2014
DOI: 10.4067/s0034-98872014000800007
|View full text |Cite
|
Sign up to set email alerts
|

Impacto clínico de un sistema de farmacovigilancia activa realizado por un farmacéutico en el reporte y subnotificación de reacciones adversas a medicamentos

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
3
0
6

Year Published

2017
2017
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(9 citation statements)
references
References 33 publications
0
3
0
6
Order By: Relevance
“…Twenty‐six studies examined the impact of IMS by different methods in both developed and developing countries. The positive effect of IMS on ADR reporting varied widely, from 1.02 to 83.9‐fold . As shown in Table , the range of effect of IMS was nearly similar to the effect of educational interventions and computerized registration.…”
Section: Resultsmentioning
confidence: 77%
See 1 more Smart Citation
“…Twenty‐six studies examined the impact of IMS by different methods in both developed and developing countries. The positive effect of IMS on ADR reporting varied widely, from 1.02 to 83.9‐fold . As shown in Table , the range of effect of IMS was nearly similar to the effect of educational interventions and computerized registration.…”
Section: Resultsmentioning
confidence: 77%
“…As shown in Table , the range of effect of IMS was nearly similar to the effect of educational interventions and computerized registration. In most of the studies, a clinical research assistant (CRA), pharmacists and/or clinical pharmacists were present in settings for intensive monitoring. ADRs were identified and collected both prospectively and retrospectively.…”
Section: Resultsmentioning
confidence: 99%
“…y que se implemente un sistema de clasificación / codificación, lo que permitirá un mejor análisis y producción de datos valiosos (25) . Para Sánchez I, la implementación de una farmacovigilancia activa aumenta la detección de RAM, evita la subnotificación existente y promueve su prevención (26) .…”
Section: Discussionunclassified
“…En cuanto a las clases de fármacos reportados como de riesgo para RAM se reportan los antibacterianos, antitrombóticos inhibidores de los CVA, antiinflamatorios no esteroideos y diuréticos 10 . Los activos más comúnmente reportados en las sustancias asociadas con un evento adverso son el tramadol, la dipirona, la glibenclamida y la furosemida 11 , además de los corticoesteroides tópicos, el fosfato sódico de betametasona y el clobetasol, que inducen el máximo número de reacciones 12 .…”
Section: Introductionunclassified